EGFR and non-small cell lung carcinoma: Emerging evidence suggests that multi-targeted combination therapies incorporating three or more molecular targeted agents (including EGFR-TKIs) may represent a promising strategy to prevent or delay the development of acquired resistance in EGFR-mutated NSCLC [56, 57].